Fleurstat - coming to a pharmacy near you, page-17

I completely agree. This has been my point all along about their business strategy. I would rather have seen revenues coming though the door years ago and VivaGel gaining traction globally. Instead they gambled it all on the FDA for a pittance more, and it has spectacularly backfired - effectively putting SPL back to where they were in 2015/16. Instead of trading around the $3-4 mark and moving upwards, which would make for a happy shareholder base, they have left themselves vulnerable to an opportunistic takeover just as they are on the cusp of greatness. A decent share price would provide some protection now, or at least a decent takeover price. I, like many here, don't want to wait for years just to get a $2/share pay day and then watch from the sidelines as SPL's technology transforms the medical world under somebody else's stewardship. We all know the potential, that's why we're invested. At the moment, it's the future we're buying into, but this BOD has got to get it right from here. They have used up their margin for error and strained investor patience beyond reason.